文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

静脉-动脉体外膜氧合支持期间的上消化道出血

Upper gastrointestinal bleeding on veno-arterial extracorporeal membrane oxygenation support.
PubMed 文献 · Ann Intensive Care · 2024-07-03
一句话结论V-A ECMO患者上消化道出血发生率10.7%,中位发生时间10天,唯一独立危险因素为消化性溃疡病史(OR=7.32),预防性质子泵抑制剂与肠内营养似乎未能提供保护。

本研究为2013-2017年单中心回顾性研究,纳入150例V-A ECMO患者(心脏外科术后65例、内科病因85例),排除24小时内死亡者。90%患者接受预防性质子泵抑制剂和肠内营养;31例因疑似上消化道出血行食管胃十二指肠镜检查,确诊16例,发生率10.7%,中位发生时间10[7-17]天。上消化道出血组 packed red blood cells 与新鲜冰冻血浆需求、机械通气时间、V-A ECMO时间、ICU及住院时间均显著增加,死亡率无显著差异;唯一独立危险因素为消化性溃疡病史(OR=7.32;95%CI[1.07-50.01],p=0.042)。作者认为肠内营养和质子泵抑制剂预防似乎未能保护V-A ECMO患者,需进一步研究评估其真实获益。

要点

  • V-A ECMO患者上消化道出血发生率为10.7%,中位发生时间10[7-17]天,即至少1/10的V-A ECMO患者会发生上消化道出血。
  • 唯一独立危险因素为消化性溃疡病史(OR=7.32;95%CI[1.07-50.01],p=0.042),该人群需重点警惕上消化道出血。
  • 上消化道出血组 packed red blood cells 与新鲜冰冻血浆需求、机械通气时间、V-A ECMO时间、ICU及住院时间均显著增加,但死亡率无显著差异。
  • 90%患者接受预防性质子泵抑制剂和肠内营养,作者认为二者似乎未能保护V-A ECMO患者,需进一步研究评估其真实获益。

适用人群与场景

  • 2013-2017年单中心V-A ECMO患者,共150例,其中心脏外科术后65例、内科病因85例。
  • 排除V-A ECMO启动后24小时内死亡的患者。
  • 分析范围从ECMO启动至拔管后5天。

诊断标准与关键阈值

  • 疑似上消化道出血者行食管胃十二指肠镜检查(EGD),确诊上消化道出血16例。

处置流程与药物剂量

  • 90%的患者接受预防性质子泵抑制剂治疗和肠内营养。
  • 所有疑似上消化道出血患者行食管胃十二指肠镜检查(EGD)。

研究设计与关键结果

  • 单中心回顾性研究纳入150例V-A ECMO病例,31例因疑似上消化道出血行EGD,确诊16例,发生率10.7%,中位发生时间10[7-17]天。
  • EGD当日临床或生物学特征无显著差异。
  • 上消化道出血组 packed red blood cells 与新鲜冰冻血浆需求、机械通气时间、V-A ECMO时间、ICU及住院时间均显著增加。
  • 上消化道出血组与无上消化道出血组死亡率无显著差异。
  • 唯一独立危险因素为消化性溃疡病史(OR=7.32;95%CI[1.07-50.01],p=0.042)。

证据类型、等级与局限

  • 证据类型:单中心回顾性研究(2013-2017年)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • V-A ECMO患者上消化道出血发生率约10.7%,中位发生在ECMO启动后10天,需在ICU病程中保持警惕。
  • 有消化性溃疡病史的V-A ECMO患者上消化道出血风险升高(OR=7.32;95%CI[1.07-50.01],p=0.042),应重点监测。
  • 作者认为肠内营养和质子泵抑制剂预防似乎未能保护V-A ECMO患者,需进一步研究评估其真实获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Patients on veno-arterial extracorporeal membrane oxygenation (V-A ECMO) support are at a high risk of hemorrhagic complications, including upper gastrointestinal bleeding (UGIB). The objective of this study was to evaluate the incidence and impact of this complication in V-A ECMO patients.

MATERIALS AND METHODS: A retrospective single-center study (2013-2017) was conducted on V-A ECMO patients, excluding those who died within 24 h. All patients with suspected UGIB underwent esophagogastroduodenoscopy (EGD) and were analyzed and compared to the remainder of the cohort, from the initiation of ECMO until 5 days after explantation.

RESULTS: A total of 150 V-A ECMO cases (65 after cardiac surgery and 85 due to medical etiology) were included. 90% of the patients received prophylactic proton pump inhibitor therapy and enteral nutrition. Thirty-one patients underwent EGD for suspected UGIB, with 16 confirmed cases of UGIB. The incidence was 10.7%, with a median occurrence at 10 [7-17] days. There were no significant differences in clinical or biological characteristics on the day of EGD. However, patients with UGIB had significant increases in packed red blood cells and fresh frozen plasma needs, mechanical ventilation duration and V-A ECMO duration, as well as in length of intensive care unit and hospital stays. There was no significant difference in mortality. The only independent risk factor of UGIB was a history of peptic ulcer (OR = 7.32; 95% CI [1.07-50.01], p = 0.042).

CONCLUSION: UGIB occurred in at least 1 out of 10 cases of V-A ECMO patients, with significant consequences on healthcare resources. Enteral nutrition and proton pump inhibitor prophylaxis did not appear to protect V-A ECMO patients. Further studies should assess their real benefits in these patients with high risk of hemorrhage.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. de Roux Q, Disli Y, Bougouin W, et al. Upper gastrointestinal bleeding on veno-arterial extracorporeal membrane oxygenation support. Ann Intensive Care. 2024. PMID: 38958791. doi:10.1186/s13613-024-01326-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。